Celularity is a clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies derived from the postpartum placenta to treat cancer, infectious diseases, and age-related conditions. The company's platform leverages placental-derived cellular sources including natural killer (NK) cells, T cells, and mesenchymal stromal cells.
Celularity is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2016
Employees
120–126
Total Funding
$452.58M
5 rounds
Last Private Valuation
$1.29B
Jan 8, 2021
Closed $10M financing: $7M senior secured term loan + up to $5M convertible notes, led by Philip A. Barach
New secured debt/convertible financing dilutes equity and signals ongoing liquidity need
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $452.58M across 5 rounds
Last updated 09-21-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Jan 8, 2021 | PIPE (concurrent with SPAC merger) Press release | $83.4M | $1.29B | Not disclosed |
| Nov 4, 2019 | Series B (warrant exercise) | $44.2M | — | Dragasac Limited (Genting Berhad) |
| May 2019 | Series B (warrant exercise) | $25.0M | — | Dragasac Limited (Genting Berhad) |
Robert J. Hariri
Founder, Chairman, and Chief Executive Officer
John R. Haines
Senior Executive Vice President, General Manager, and Chief Administrative Officer
Brad Glover
Executive Vice President and Chief Operating Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Fate Therapeutics
Clinical-stage biotech developing off-the-shelf CAR NK immunotherapies from iPSC-derived cells, including FT576 targeting BCMA.
Dragonfly Therapeutics
Developing TriNKETs platform-based NK cell therapies to engage innate and adaptive immune systems.
ONK Therapeutics
Gene-edited NK cell therapy company with CAR NK candidates for AML, multiple myeloma, and solid tumors.
Artiva Biotherapeutics
Developing off-the-shelf NK cell therapies as an alternative to CAR-T with improved safety profile.
Celularity went public via SPAC merger with GX Acquisition Corp. and has traded on Nasdaq under CELU since July 19, 2021. In September 2026 Nasdaq confirmed it had regained compliance with the minimum bid price and market value of listed securities rules, but it remained deficient for late Form 10-Q filings for the first two quarters of 2026.
Celularity shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Celularity had a valuation of approximately $1.29B at the time of its public offering. Current market capitalization fluctuates with the share price.
Celularity raised $452.58M across 5 disclosed funding rounds prior to its public listing.
Celularity was founded by Robert J. Hariri in 2016.
Celularity is headquartered in Florham Park, NJ, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.